Olaparib, a poly (ADP)-ribose polymerase (PARP) inhibitor, demonstrated substantial delay until progression when administered to women as a maintenance therapy with BRCA-mutant recurrent ovarian cancer.
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content